HIK.L vs HRTX
HIK.L: Hikma Pharmaceuticals is a global provider of generic, branded, and injectable medicines with a significant footprint in the US and MENA markets. HRTX: Heron Therapeutics is a biotech company focused on commercializing extended-release postoperative pain and antiemetic therapies for acute care and oncology patients.
Side-by-side fundamentals
| Metric | HIK.L | HRTX | Edge |
|---|---|---|---|
| Price | £16.46 | $0.3582 | |
| Market cap | $4.5B | $68M | |
| Net margin FY to 2025-12-31, filed 2026-03-18 | +12.2% | n/a | |
| Gross margin FY to 2025-12-31, filed 2026-03-18 | +43.0% | n/a | |
| ROE | +15.6% | -140.9% | HIK.L higher |
| ROA FY2025, SEC XBRL | n/a | -7.9% | |
| Debt / equity as of 2026-09-03 | n/a | 20.65 | |
| Revenue growth (YoY) as of 2026-09-03 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | n/a | 1.11 | |
| 1-year return | -9.8% | -73.5% | HIK.L higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.